Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
About this market
Globally, the prevalence of multiple sclerosis has increased due to genetic and environmental factors. Another reason which could be attributed to the increasing prevalence is the advances in diagnostic techniques in this therapy area. The prevalence of autoimmune diseases such as type 1 diabetes and certain infections such as infectious mononucleosis also increases the risk of multiple sclerosis. In 2008, the global prevalence of multiple sclerosis was estimated to be 0.031%, which increased to 0.032% in 2013. The prevalence of multiple sclerosis in Europe is also high. High disease prevalence drives the demand for drugs, thereby driving the growth of the market. analysts have predicted that the multiple sclerosis drugs market will register a CAGR of close to 6% by 2023.
Market Overview
Strong drug pipeline
With the increase in the prevalence of multiple sclerosis, there is a high unmet need for a strong pipeline of disease-modifying drugs. Current drugs for multiple sclerosis slow down the disease progression, but in many patients' responses to drugs are often variable and suboptimal. Ongoing R&D for the development of new drugs has resulted in the development of a strong drug pipeline for the treatment of multiple sclerosis. Therefore, the drug development initiatives by companies are expected to dive the market in the forecast period.
Side effects of multiple sclerosis drugs
The side effects associated with multiple sclerosis drugs can range from mild to serious. Therefore, side effects associated with these drugs can lead to low patient compliance and may hinder the growth of the global multiple sclerosis drugs market.
For the detailed list of factors that will drive and challenge the growth of the multiple sclerosis drugs market during the 2019-2023, view our report.
Competitive Landscape
The market appears to be moderately concentrated and with the presence of limited vendors. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
Globally, the prevalence of multiple sclerosis has increased due to genetic and environmental factors. Another reason which could be attributed to the increasing prevalence is the advances in diagnostic techniques in this therapy area. The prevalence of autoimmune diseases such as type 1 diabetes and certain infections such as infectious mononucleosis also increases the risk of multiple sclerosis. In 2008, the global prevalence of multiple sclerosis was estimated to be 0.031%, which increased to 0.032% in 2013. The prevalence of multiple sclerosis in Europe is also high. High disease prevalence drives the demand for drugs, thereby driving the growth of the market. analysts have predicted that the multiple sclerosis drugs market will register a CAGR of close to 6% by 2023.
Market Overview
Strong drug pipeline
With the increase in the prevalence of multiple sclerosis, there is a high unmet need for a strong pipeline of disease-modifying drugs. Current drugs for multiple sclerosis slow down the disease progression, but in many patients' responses to drugs are often variable and suboptimal. Ongoing R&D for the development of new drugs has resulted in the development of a strong drug pipeline for the treatment of multiple sclerosis. Therefore, the drug development initiatives by companies are expected to dive the market in the forecast period.
Side effects of multiple sclerosis drugs
The side effects associated with multiple sclerosis drugs can range from mild to serious. Therefore, side effects associated with these drugs can lead to low patient compliance and may hinder the growth of the global multiple sclerosis drugs market.
For the detailed list of factors that will drive and challenge the growth of the multiple sclerosis drugs market during the 2019-2023, view our report.
Competitive Landscape
The market appears to be moderately concentrated and with the presence of limited vendors. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
